• Education
    • Higher Education
    • Scholarships & Grants
    • Online Learning
    • School Reforms
    • Research & Innovation
  • Lifestyle
    • Travel
    • Food & Drink
    • Fashion & Beauty
    • Home & Living
    • Relationships & Family
  • Technology & Startups
    • Software & Apps
    • Startup Success Stories
    • Startups & Innovations
    • Tech Regulations
    • Venture Capital
    • Artificial Intelligence
    • Cybersecurity
    • Emerging Technologies
    • Gadgets & Devices
    • Industry Analysis
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy
Today Headline
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
Today Headline
No Result
View All Result
Home Science & Environment Medical Research

Treatment decisions on basis of biomarker-based test can be harmful

July 7, 2025
in Medical Research
Reading Time: 3 mins read
A A
0
biomarker research
2
SHARES
5
VIEWS
Share on FacebookShare on Twitter


biomarker research
Credit: Unsplash/CC0 Public Domain

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the pros and cons of biomarker-based tests to inform decisions about adjuvant chemotherapy for patients with a certain type of breast cancer, i.e., first-time, hormone receptor-positive and HER2/neu-negative breast cancer.

According to the findings, women with breast cancer aged up to 50 or premenopausal should not decide against adjuvant chemotherapy on the basis of the “MammaPrint” or “Oncotype DX” biomarker-based tests. This is because regardless of whether their lymph nodes are already affected by cancer or not, they may then forgo treatment that could prevent a recurrence.

Biomarker-based tests determine whether the risk of a tumor recurring after surgical removal is low or high. These tests are primarily used when the individual risk of recurrence cannot be reliably determined by means of clinical factors such as certain tumor characteristics. If the risk of recurrence is low, chemotherapy would be an unnecessary burden.

For primary breast cancer, the German statutory health insurance funds currently reimburse four biomarker-based tests: MammaPrint, Oncotype DX, EndoPredict and Prosigna. Doctors can currently use these tests in outpatient care if the patient’s lymph nodes have not yet been affected by the cancer.

Results depend on menopausal status

Meaningful data from randomized controlled trials (RCTs) is only available for MammaPrint (MINDACT study) and Oncotype DX (RxPONDER and TAILORx studies).

IQWiG draws the following main conclusions from these three studies:

  • In premenopausal patients (up to 50 years of age), RCT evidence does not support the use of a biomarker-based test to guide breast cancer therapy.
  • In postmenopausal patients (over 50 years of age), RCT evidence supports the use of a biomarker-based test (Oncotype DX) to guide breast cancer therapy.

It is not possible to verify whether this evaluation also applies to other biomarker-based tests, such as EndoPredict or Prosigna, as no suitable data is available.

Summarizing the results of the IQWiG report, Daniel Fleer, Deputy Head of IQWiG’s Non-Drug Interventions Department, says, “The risk of mistakenly forgoing chemotherapy on the basis of a biomarker-based test is therefore substantially higher in premenopausal than in postmenopausal breast cancer patients.”

Procedure of report production

In May 2023, the Federal Joint Committee (G-BA) commissioned IQWiG to assess the use of biomarker-based tests to inform decisions about adjuvant systemic chemotherapy for primary breast cancer involving one to three lymph nodes.

In September 2023, the G-BA also commissioned the Institute to assess the same question for premenopausal patients with primary breast cancer without lymph node involvement. IQWiG published the preliminary results, the preliminary report, in June 2024 and invited comments.

Following the commenting procedure, the report was revised and sent as a final report to G-BA, the contracting agency, in October 2024. The written comments submitted on the preliminary report were published in a separate document at the same time as the final report in November 2024. An English translation was published in July 2025.

More information:
Biomarker-based tests for deciding for or against adjuvant systemic chemotherapy in primary breast cancer with involvement of 1 to 3 lymph nodes and in premenopausal patients without lymph node involvement (2025). DOI: 10.60584/d23-01b_en

Provided by
Institute for Quality and Efficiency in Health Care


Citation:
Breast cancer: Treatment decisions on basis of biomarker-based test can be harmful (2025, July 7)
retrieved 7 July 2025
from https://medicalxpress.com/news/2025-07-breast-cancer-treatment-decisions-basis.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.




biomarker research
Credit: Unsplash/CC0 Public Domain

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the pros and cons of biomarker-based tests to inform decisions about adjuvant chemotherapy for patients with a certain type of breast cancer, i.e., first-time, hormone receptor-positive and HER2/neu-negative breast cancer.

According to the findings, women with breast cancer aged up to 50 or premenopausal should not decide against adjuvant chemotherapy on the basis of the “MammaPrint” or “Oncotype DX” biomarker-based tests. This is because regardless of whether their lymph nodes are already affected by cancer or not, they may then forgo treatment that could prevent a recurrence.

Biomarker-based tests determine whether the risk of a tumor recurring after surgical removal is low or high. These tests are primarily used when the individual risk of recurrence cannot be reliably determined by means of clinical factors such as certain tumor characteristics. If the risk of recurrence is low, chemotherapy would be an unnecessary burden.

For primary breast cancer, the German statutory health insurance funds currently reimburse four biomarker-based tests: MammaPrint, Oncotype DX, EndoPredict and Prosigna. Doctors can currently use these tests in outpatient care if the patient’s lymph nodes have not yet been affected by the cancer.

Results depend on menopausal status

Meaningful data from randomized controlled trials (RCTs) is only available for MammaPrint (MINDACT study) and Oncotype DX (RxPONDER and TAILORx studies).

IQWiG draws the following main conclusions from these three studies:

  • In premenopausal patients (up to 50 years of age), RCT evidence does not support the use of a biomarker-based test to guide breast cancer therapy.
  • In postmenopausal patients (over 50 years of age), RCT evidence supports the use of a biomarker-based test (Oncotype DX) to guide breast cancer therapy.

It is not possible to verify whether this evaluation also applies to other biomarker-based tests, such as EndoPredict or Prosigna, as no suitable data is available.

Summarizing the results of the IQWiG report, Daniel Fleer, Deputy Head of IQWiG’s Non-Drug Interventions Department, says, “The risk of mistakenly forgoing chemotherapy on the basis of a biomarker-based test is therefore substantially higher in premenopausal than in postmenopausal breast cancer patients.”

Procedure of report production

In May 2023, the Federal Joint Committee (G-BA) commissioned IQWiG to assess the use of biomarker-based tests to inform decisions about adjuvant systemic chemotherapy for primary breast cancer involving one to three lymph nodes.

In September 2023, the G-BA also commissioned the Institute to assess the same question for premenopausal patients with primary breast cancer without lymph node involvement. IQWiG published the preliminary results, the preliminary report, in June 2024 and invited comments.

Following the commenting procedure, the report was revised and sent as a final report to G-BA, the contracting agency, in October 2024. The written comments submitted on the preliminary report were published in a separate document at the same time as the final report in November 2024. An English translation was published in July 2025.

More information:
Biomarker-based tests for deciding for or against adjuvant systemic chemotherapy in primary breast cancer with involvement of 1 to 3 lymph nodes and in premenopausal patients without lymph node involvement (2025). DOI: 10.60584/d23-01b_en

Provided by
Institute for Quality and Efficiency in Health Care


Citation:
Breast cancer: Treatment decisions on basis of biomarker-based test can be harmful (2025, July 7)
retrieved 7 July 2025
from https://medicalxpress.com/news/2025-07-breast-cancer-treatment-decisions-basis.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.



Tags: Health ResearchHealth Research NewsHealth ScienceMedicine ResearchMedicine Research NewsMedicine Science
Previous Post

California, 17 other states challenge ‘suspicionless’ stops by masked ICE agents in L.A.

Next Post

CSA invest $3.9 million in five smartEarth proposals

Related Posts

Review compares efficacy, safety of treatments for hidradenitis suppurativa

Review compares efficacy, safety of treatments for hidradenitis suppurativa

July 8, 2025
4
Study reveals accurate association between weak handgrip and a host of diseases among over-50s

Study reveals accurate association between weak handgrip and a host of diseases among over-50s

July 7, 2025
9
Next Post

CSA invest $3.9 million in five smartEarth proposals

  • Trending
  • Comments
  • Latest
Family calls for change after B.C. nurse dies by suicide after attacks on the job

Family calls for change after B.C. nurse dies by suicide after attacks on the job

April 2, 2025
Pioneering 3D printing project shares successes

Product reduces TPH levels to non-hazardous status

November 27, 2024

Police ID man who died after Corso Italia fight

December 23, 2024

Hospital Mergers Fail to Deliver Better Care or Lower Costs, Study Finds todayheadline

December 31, 2024
Harris tells supporters 'never give up' and urges peaceful transfer of power

Harris tells supporters ‘never give up’ and urges peaceful transfer of power

0
Des Moines Man Accused Of Shooting Ex-Girlfriend's Mother

Des Moines Man Accused Of Shooting Ex-Girlfriend’s Mother

0

Trump ‘looks forward’ to White House meeting with Biden

0
Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

0

Oil prices ease as traders assess US tariffs, OPEC+ output hike

July 8, 2025
‘High probability of extinction’: Urgent plea for action to save southern resident orcas

‘High probability of extinction’: Urgent plea for action to save southern resident orcas

July 8, 2025
Egypt Independent

Blaze at Cairo telecommunications building injures 22, mostly from smoke inhalation

July 8, 2025
Walmart is selling the 'best' $259 rolling storage dresser for $160 that buyers compare to drawer units 'at Ikea'

Walmart is selling the 'best' $259 rolling storage dresser for $160 that buyers compare to drawer units 'at Ikea' todayheadline

July 8, 2025

Recent News

Oil prices ease as traders assess US tariffs, OPEC+ output hike

July 8, 2025
4
‘High probability of extinction’: Urgent plea for action to save southern resident orcas

‘High probability of extinction’: Urgent plea for action to save southern resident orcas

July 8, 2025
2
Egypt Independent

Blaze at Cairo telecommunications building injures 22, mostly from smoke inhalation

July 8, 2025
6
Walmart is selling the 'best' $259 rolling storage dresser for $160 that buyers compare to drawer units 'at Ikea'

Walmart is selling the 'best' $259 rolling storage dresser for $160 that buyers compare to drawer units 'at Ikea' todayheadline

July 8, 2025
2

TodayHeadline is a dynamic news website dedicated to delivering up-to-date and comprehensive news coverage from around the globe.

Follow Us

Browse by Category

  • Africa
  • Asia
  • Basketball
  • Business & Finance
  • Climate Change
  • Crime & Justice
  • Cybersecurity
  • Economic Policies
  • Elections
  • Entertainment
  • Entrepreneurship
  • Environmental Policies
  • Europe
  • Football
  • Gadgets & Devices
  • Health
  • Medical Research
  • Mental Health
  • Middle East
  • Motorsport
  • Olympics
  • Politics
  • Public Health
  • Relationships & Family
  • Science & Environment
  • Software & Apps
  • Space Exploration
  • Sports
  • Stock Market
  • Technology & Startups
  • Tennis
  • Travel
  • Uncategorized
  • Us & Canada
  • Wildlife & Conservation
  • World News

Recent News

Oil prices ease as traders assess US tariffs, OPEC+ output hike

July 8, 2025
‘High probability of extinction’: Urgent plea for action to save southern resident orcas

‘High probability of extinction’: Urgent plea for action to save southern resident orcas

July 8, 2025
  • Education
  • Lifestyle
  • Technology & Startups
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy

© 2024 Todayheadline.co

Welcome Back!

OR

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Business & Finance
  • Corporate News
  • Economic Policies
  • Entrepreneurship
  • Market Trends
  • Crime & Justice
  • Court Cases
  • Criminal Investigations
  • Cybercrime
  • Legal Reforms
  • Policing
  • Education
  • Higher Education
  • Online Learning
  • Entertainment
  • Awards & Festivals
  • Celebrity News
  • Movies
  • Music
  • Health
  • Fitness & Nutrition
  • Medical Breakthroughs
  • Mental Health
  • Pandemic Updates
  • Lifestyle
  • Fashion & Beauty
  • Food & Drink
  • Home & Living
  • Politics
  • Elections
  • Government Policies
  • International Relations
  • Legislative News
  • Political Parties
  • Africa
  • Asia
  • Europe
  • Middle East
  • Artificial Intelligence
  • Cybersecurity
  • Emerging Technologies
  • Gadgets & Devices
  • Industry Analysis
  • Basketball
  • Football
  • Motorsport
  • Olympics
  • Climate Change
  • Environmental Policies
  • Medical Research
  • Science & Environment
  • Space Exploration
  • Wildlife & Conservation
  • Sports
  • Tennis
  • Technology & Startups
  • Software & Apps
  • Startup Success Stories
  • Startups & Innovations
  • Tech Regulations
  • Venture Capital
  • Uncategorized
  • World News
  • Us & Canada
  • Public Health
  • Relationships & Family
  • Travel
  • Research & Innovation
  • Scholarships & Grants
  • School Reforms
  • Stock Market
  • TV & Streaming
  • Advertise with Us
  • Privacy & Policy
  • About us
  • Contact

© 2024 Todayheadline.co